Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

Продолжение лечения тирзепатидом для поддержания снижения массы тела у взрослых с ожирением
Juan P. Frías, Julio Rosenstock, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa E. Connery, Shuyu Zhang, Mathijs C. Bunck, Harold Edward Bays, Naveed A. Sattar, Wen‐Yuan Lin, Ronald Brazg, Kuo‐Chin Huang, Purvi Mehra, Athena Philis‐Tsimikas, S Geller, John Nardandrea, Timothy Richard Smith, Alexander V. Murray, John C.H. Reed, Deborah Bade Horn, Ran Liao, Irina Jouravskaya, Madhumita A. Murphy, Jose Osvaldo Fretes, Maria Jimena Coronel, Lucas L Gutnisky, Gustavo Daniel Frechtel, Elizabeth Gelersztein, Diego Aizenberg, Natacha Maldonado, Márcio Pereira, Queulla G Santos, Camila Calil Salim, Luís Henrique Santos Canani, Bruno Halpern, Luis AT Russo, Joselita Bodart, Danilo V Neto, Gustavo Augusto, Silmara Leite, Yi‐Ching Yang, Chien‐Ning Huang, David Fitz-Patrick, Cindy HT Pau, Phillip D. Toth, G.H. Freeman, Donald F Gardner, Alan G Wynne, Juan Loy, Stacey Layle, James H. Bergthold, José de Souza, Venkatesh Nadar, G Angulo, Ken Cohen, Michael G. Vaughn, Altagracia Aurora Alcantara-Gonzalez, Seth B. Forman, John M. Agaiby, Neil J. Fraser, Robert A. Jenders, Kim Barbel-Johnson, Ronald K. Mayfield, Carl D Vance, Kevin T Prier, Michael J. Lillestol, Douglas Scott Denham, Jean Park, ERIC J. KLEIN, Peter E Bressler, Shamaila Aslam, Leslie J. Klaff, Martha Gomez-Cuellar, Joanna T Van, Jean-Louis Sélam, John Kim, Dwight Blake, John Gabriel, Samir Arora, Michael J McCartney, Royce Keith Solano, Steven K Brodie, John P Nardandrea, SURMOUNT-4 Investigators, Wen-Yuan Lin, Luis Augusto Tavares Russo, Cindy Ta Pau, Mathijs C. M. Bunck, Carl Vance, Camila P Calil Salim, Lucas Gutnisky, George H Freeman, Neil J Fraser, Jean Y Park
2023-12-11

obesityrandomized withdrawal trialtirzepatideweight maintenanceweight reduction
Importance: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. Design, Setting, and Participants: This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes. Interventions: Participants (n = 783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks. Main Outcomes and Measures: The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80% of the weight loss during the lead-in period. Results: Participants (n = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo. Conclusions and Relevance: In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. Trial Registration: ClinicalTrials.gov Identifier: NCT04660643.
1
After a 36-week tirzepatide lead-in, participants achieved a mean weight reduction of 20.9%.
2
At week 88, 89.5% of participants continuing tirzepatide maintained at least 80% of lead-in weight loss, compared with 16.6% switching to placebo.
3
Continuing tirzepatide for 52 additional weeks produced a 5.5% mean weight decrease, whereas switching to placebo produced a 14.0% increase.
4
Overall weight reduction from baseline to week 88 was 25.3% with continued tirzepatide versus 9.9% after switching to placebo; adverse events were mostly mild-to-moderate gastrointestinal events.
5
The between-group difference in weight change from weeks 36 to 88 was -19.4 percentage points (95% CI, -21.2% to -17.7%; P < .001).

Adults with obesity (without diabetes) undergoing continued tirzepatide treatment with diet and physical activity

Maintenance of initial weight reduction during continued tirzepatide treatment versus withdrawal to placebo

Publication Details
Publication Date
2023-12-11
Journal
Publisher
ISSN
Cited by
971
Access Type
Author Information
Authors
Juan P. Frías
Julio Rosenstock
Louis J. Aronne
Nadia N. Ahmad
Sean Wharton
Lisa E. Connery
Shuyu Zhang
Mathijs C. Bunck
Harold Edward Bays
Naveed A. Sattar
Wen‐Yuan Lin
Ronald Brazg
Kuo‐Chin Huang
Purvi Mehra
Athena Philis‐Tsimikas
S Geller
John Nardandrea
Timothy Richard Smith
Alexander V. Murray
John C.H. Reed
Deborah Bade Horn
Ran Liao
Irina Jouravskaya
Madhumita A. Murphy
Jose Osvaldo Fretes
Maria Jimena Coronel
Lucas L Gutnisky
Gustavo Daniel Frechtel
Elizabeth Gelersztein
Diego Aizenberg
Natacha Maldonado
Márcio Pereira
Queulla G Santos
Camila Calil Salim
Luís Henrique Santos Canani
Bruno Halpern
Luis AT Russo
Joselita Bodart
Danilo V Neto
Gustavo Augusto
Silmara Leite
Yi‐Ching Yang
Chien‐Ning Huang
David Fitz-Patrick
Cindy HT Pau
Phillip D. Toth
G.H. Freeman
Donald F Gardner
Alan G Wynne
Juan Loy
Stacey Layle
James H. Bergthold
José de Souza
Venkatesh Nadar
G Angulo
Ken Cohen
Michael G. Vaughn
Altagracia Aurora Alcantara-Gonzalez
Seth B. Forman
John M. Agaiby
Neil J. Fraser
Robert A. Jenders
Kim Barbel-Johnson
Ronald K. Mayfield
Carl D Vance
Kevin T Prier
Michael J. Lillestol
Douglas Scott Denham
Jean Park
ERIC J. KLEIN
Peter E Bressler
Shamaila Aslam
Leslie J. Klaff
Martha Gomez-Cuellar
Joanna T Van
Jean-Louis Sélam
John Kim
Dwight Blake
John Gabriel
Samir Arora
Michael J McCartney
Royce Keith Solano
Steven K Brodie
John P Nardandrea
SURMOUNT-4 Investigators
Wen-Yuan Lin
Luis Augusto Tavares Russo
Cindy Ta Pau
Mathijs C. M. Bunck
Carl Vance
Camila P Calil Salim
Lucas Gutnisky
George H Freeman
Neil J Fraser
Jean Y Park
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%